Regeneron Pharmaceuticals | REGN - Cash And Equivalent


Regeneron Pharmaceuticals reported $3.66B in Cash and Equivalent for its fiscal quarter ending in September of 2026.





Cash And Equivalent Change Date
AbbVie USD 6.57B 2.82B Jun/2026
Agenus USD 18.74M 16.26M Jun/2026
Agios Pharmaceuticals USD 99.65M 13.95M Jun/2026
Alnylam Pharmaceuticals USD 1.75B 46.02M Sep/2026
Amgen USD 13.99B 1.95B Jun/2026
Astellas Pharma JPY 281.6B 93.23B Mar/2026
AstraZeneca USD 4.89B 2.67B Jun/2026
Biogen USD 1.3B 18.9M Sep/2026
BioMarin Pharmaceutical USD 874M 1.35B Jun/2026
Bristol-Myers Squibb USD 9.57B 852M Sep/2026
Eli Lilly USD 4.89B 4.07B Sep/2026
Gilead Sciences USD 3.18B 4.45B Jun/2026
GlaxoSmithKline GBP 3.1B 337M Jun/2026
Incyte USD 3.85B 127.8M Sep/2026
Ionis Pharmaceuticals USD 350.06M 1.57B Jun/2026
J&J USD 16.91B 3.51B Sep/2026
Kyowa Hakko Kirin JPY 218.77B 15.83B Dec/2025
Merck USD 6.85B 1.52B Jun/2026
Moderna USD 1.72B 185M Jun/2026
Neurocrine Biosciences USD 332.4M 65.9M Jun/2026
Novartis USD 7.62B 739M Jun/2026
Novartis USD 6.88B 2.68B Mar/2026
Pfizer USD 976M 727M Jun/2026
Puma Biotechnology USD 53.52M 1.14M Sep/2025
Regeneron Pharmaceuticals USD 3.66B 1.2B Sep/2026
Roche Holding CHF 7.55B 579M Jun/2025
Sanofi EUR 5.54B 2.11B Mar/2026
Sarepta Therapeutics USD 571.15M 106.7M Jun/2026
Teva Pharmaceutical Industries USD 3.74B 185M Mar/2026
Ultragenyx Pharmaceutical USD 125M 50M Jun/2026
United Therapeutics USD 1.8B 523.5M Jun/2026
Vertex Pharmaceuticals USD 7.85B 605.7M Jun/2026